Prolonged half-life of Argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 245-246

  Athar, Uzma ^a,c   Husain, Juhi ^a   Hudson, Jane ^b   Lynch, Jennie ^b   Gajra, Ajeet ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

^c Regional Oncology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; LUPUS ANTICOAGULANT; WARFARIN;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DOSE KIDNEY FUNCTION RELATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; MITRAL VALVE PROSTHESIS; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; THROMBOSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; HALF-LIFE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PERITONEAL DIALYSIS; PIPECOLIC ACIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME; WARFARIN;

EID: 39749181614     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21072     Document Type: Article

References (6)

1. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharm 2004;38:25-29.
2. Kubiak DW, Szumita PM. Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharm 2005;39:1119-1123.
3. de Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharm 2003;37:1237-1240.
4. Pendleton R, Wheeler M. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome. Ann Pharm 2006;40:972-976.
5. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban on prothrombin time and INR values. Am J Clin Pathol 2004;121:593-599.
6. Genzen JR, Miller J. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Coagulat Transfusion Med 2005;124:586-593.